229003-14-9Relevant academic research and scientific papers
INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
-
Page/Page column 15-16, (2012/03/10)
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
Discovery of novel aminothiadiazole amides as selective EP3 receptor antagonists
Hilfiker, Mark A.,Wang, Ning,Hou, Xiaoping,Du, Zhimin,Pullen, Mark A.,Nord, Melanie,Nagilla, Rakesh,Fries, Harvey E.,Wu, Charlene W.,Sulpizio, Anthony C.,Jaworski, Jon-Paul,Morrow, Dwight,Edwards, Richard M.,Jin, Jian
scheme or table, p. 4292 - 4295 (2010/05/18)
This Letter discloses a series of 2-aminothiadiazole amides as selective EP3 receptor antagonists. SAR optimization resulted in compounds with excellent functional activity in vitro. In addition, efforts to optimize DMPK properties in the rat are discussed. These efforts have resulted in the identification of potent, selective EP3 receptor antagonists with excellent DMPK properties suitable for in vivo studies.
INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS
-
Page/Page column 15, (2010/11/28)
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
